FDA Announces Update on MOU for Compounding Pharmacies

by | May 15, 2020 | All Posts, COVID-19, FDA

On May 13, a standard memorandum of understanding, also known as a MOU, between the FDA and the states was made available for public viewing as part of the regulatory process. The article states that this marks a significant milestone in the agency’s regulation of human drug compounding and reflects years of collaborative dialogue and stakeholder input.

Thank you for reading this post, don't forget to subscribe!

To read more on the article, follow the link below:

FDA Announces Latest Step Toward Finalizing Memorandum of Understanding with States Addressing Compounded Drug Distribution, While Preserving Access

Have questions? Our experts are here to help. Fill out “Fact Check Form” for answers to this or any other subject related to health & science including COVID-19. Our scientific experts are committed to providing answers to help you in navigating these challenging times.

Who We Are

Eagle consultants and scientists are helping compounding facilities implement successful quality systems. Our team has over 200 years of combined experience in the FDA-regulated pharmaceutical industry and can provide guidance in establishing the systems and processes that will help facilities producing compounded medications meet and exceed regulatory expectations. Follow the link below to learn more about our consulting services.

Eagle Analytical
Verified by MonsterInsights